BEAT
HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.
HeartBeam, Inc. (BEAT) is rated D+ (1.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Revisions (F). The rating has held at D+ for 6 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | C+ (2.5) | D+ (1.8) | C (2.2) | D+ (1.6) | F (0.0) | D+ (1.6) |
| 2026-11-10 | C+ (2.5) | C+ (2.5) | C (2.2) | D+ (1.5) | F (0.0) | D+ (1.7) |
| 2026-11-03 | C+ (2.5) | C+ (2.5) | C (2.3) | D+ (1.7) | F (0.0) | D+ (1.8) |
| 2026-10-27 | C+ (2.5) | C+ (2.5) | C (2.2) | D (1.4) | F (0.0) | D+ (1.7) |
| 2026-10-20 | C+ (2.5) | C+ (2.5) | C (2.2) | D (1.3) | F (0.0) | D+ (1.7) |